FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL							
DMB Number:	3235-0287						
Estimated average burden							
ours per respon	se 0.5						

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

riiii or 1y	pe Response	8)											-1-		11 0=					
1. Name and Address of Reporting Person * LARSON BRENT L					2. Issuer Name and Ticker or Trading Symbol NAVIDEA BIOPHARMACEUTICALS, INC. [NAVB]								5	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X Officer (give title below) Other (specify below)						
(Last) (First) (Middle) 5600 BLAZER PARKWAY, SUITE 200					3. Date of Earliest Transaction (Month/Day/Year) 04/01/2015										EVP, C	CFO, Treas a	and Sec	<u>'y</u>		
(Street) DUBLIN, OH US 43017				4. If Amendment, Date Original Filed(Month/Day/Year)									6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person Form filed by More than One Reporting Person							
(City		(State)	(Zip	p)			Tal	hle I - Non	-Der	ivative S	ecurit	ties Ac	anir	ed Disno	sed of or l	Reneficially	Owne	ď		
(Instr. 3) Date			2. Transact Date (Month/Da	y/Year)	2A. Deemed Execution Date, if		3. Transaction Code (Instr. 8)		4. Securities Acquire (A) or Disposed of (Instr. 3, 4 and 5)			ed D)	D) Beneficially Owned Following Reported Transaction(s)			6. Ownership Form:		7. Nature of Indirect Beneficial Ownership		
					(Mont	n/Day/ Y e	ear)	Code	V	Amount	(A) or (D)	Pric	ce	(Instr. 3 and 4)			()		nstr. 4)	
Common	Stock		04/01/201	15				S ⁽¹⁾		20,000	D	\$ 1.57' (2)	75	322,237	,		D			
Common	Stock													98,081			I	b:	y 01(k)	
indirectly.	•	separate line		ble II - D	Deriva	tive Secu	riti	ies Acquire	Per con the	sons whatained if form dis	n this splays of, or l	form s a cu Benefi	are irren	not requitly valid	uired to re I OMB cor	formation spond un atrol numb	less	SEC	1474 (9- 02)	
1. Title of	2	3. Transactio	on 3A	(e Deemed	<i>e.g.</i> , pt	its, calls, 4.	wa	5. Number		•				le and	8 Price of	9. Number	of 10.		11. Nature	
Derivative Security (Instr. 3) Derivative Or Exercise (Instr. 3) Price of Derivative Security		Date	Year) Exec			Transaction Code			and	l Expirati	on Da	te A	Amor Jnde Secur	unt of crlying rities : 3 and	Derivative Security (Instr. 5)	Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	Ownersl Form of Derivati Security Direct (I or Indire	nership m of rivative curity: rect (D) Indirect	hip of Indirect Beneficia Ownershi (Instr. 4) D)	
						Code	V	(A) (D)	Da Exc	te ercisable	Expira Date	ation T	Γitle	Amount or Number of Shares						
Repor	ting O	wners																		
]	Relationsh	ips											
Reporting Owner Name / Address Direct					or 10% Owner Officer Other															

Signatures

LARSON BRENT L

DUBLIN, OH US 43017

William J. Kelly, attorney-in-fact	04/03/2015
Signature of Reporting Person	Date

Explanation of Responses:

5600 BLAZER PARKWAY, SUITE 200

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- $\textbf{(1)} \ \ Sales \ effected \ pursuant \ to \ a \ 10b5-1 \ trading \ plan \ adopted \ by \ Mr. \ Larson \ on \ March \ 13, 2015.$

EVP, CFO, Treas and Sec'y

(2) Commission, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.